MYOMO, INC.

Myomo, Inc. manufactures the MyoPro®, an electronically controlled orthotic brace designed to restore functional arm and hand movement in patients with upper-limb paralysis. The device is indicated for individuals with stroke, brachial plexus injury (BPI), cerebral palsy, and other neuromuscular diseases or injuries. The MyoPro uses surface electromyography (sEMG) technology to detect residual muscle signals and trigger controlled electrical stimulation, enabling users to perform functional activities during therapy and in home settings. The company markets to both clinical rehabilitation providers and individual patients. Myomo has achieved Medicare reimbursement under DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) fee schedules, with CPT codes L8701 and L8702 established as of April 2024. The device is custom-fabricated for individual patients and is used primarily in stroke recovery, brachial plexus injury treatment, and veteran rehabilitation programs. The company emphasizes improved activities of daily living (ADL) outcomes and quality-of-life restoration. Myomo supports clinical education through webinars for clinicians, providers, and industry partners. The MyoPro represents a non-invasive, wearable neuroprosthetic approach to upper-limb rehabilitation, combining orthotic support with functional electrical stimulation technology.